Global Diabetic Neuropathy Market 2014-2018

2014-05-09
Price :
Published : May-2014
No. of Pages : 55

Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.

TechNavio’s analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, the Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Eli Lilly and Co.
  • Janssen Pharmaceuticals Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • Actavis plc
  • Cephalon Inc.
  • MEDA Pharma GmbH & Co. KG

Key Market Driver

  • Increasing Global Diabetic Population.
  • For a full, detailed list, view our report.

Key Market Challenge

  • High Failure Rate in Clinical Trials.
  • For a full, detailed list, view our report.

Key Market Trend

  • Increasing R&D Activities.
  • For a full, detailed list, view our report.

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Therapeutics
Publisher : Technavio
More Reports
Title Price Buy Now

Top Trends in Healthcare and OTC 2017: Exploring OTC medication, vitamins, minerals and supplements; functional food and drink; and sports nutrition categories

Top Trends in Healthcare and OTC 2017: Exploring OTC medication, vitamins, minerals and supplements; functional food and drink; and sports nutrition categories Summary Global consumers are becoming more health-conscious as a reaction to rising obesity levels and lifestyle-related illnesses, such as diabetes, in the modern world. Consumers' busy lives are a major driver for the healthcare and OTC market as people opt for more convenient, multifunctional, and personalized products that better target their specific needs. Over-the-counter (OTC) drugs are those sold directly to a consumer without a prescription from a healthcare professional, as compared to prescription drugs, which may be sold only to consumers possessing a valid prescription. The pressures of modern life are taking their......
$3450

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

Articular Cartilage Defect Global Clinical Trials Review, H1, 2017

Articular Cartilage Defect Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Articular Cartilage Defect Global Clinical Trials Review, H1, 2017" provides an overview of Articular Cartilage Defect clinical trials scenario. This report provides top line data relating to the clinical trials on Articular Cartilage Defect. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Ascites Global Clinical Trials Review, H1, 2017

Ascites Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Ascites Global Clinical Trials Review, H1, 2017" provides an overview of Ascites clinical trials scenario. This report provides top line data relating to the clinical trials on Ascites. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated fro......
$2500

Asperger Syndrome Global Clinical Trials Review, H1, 2017

Asperger Syndrome Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Asperger Syndrome Global Clinical Trials Review, H1, 2017" provides an overview of Asperger Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Asperger Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Arterial Calcification Global Clinical Trials Review, H1, 2017

Arterial Calcification Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Arterial Calcification Global Clinical Trials Review, H1, 2017" provides an overview of Arterial Calcification clinical trials scenario. This report provides top line data relating to the clinical trials on Arterial Calcification. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Arterial Stiffness Global Clinical Trials Review, H1, 2017

Arterial Stiffness Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Arterial Stiffness Global Clinical Trials Review, H1, 2017" provides an overview of Arterial Stiffness clinical trials scenario. This report provides top line data relating to the clinical trials on Arterial Stiffness. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Arterial Thrombosis Global Clinical Trials Review, H1, 2017

Arterial Thrombosis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Arterial Thrombosis Global Clinical Trials Review, H1, 2017" provides an overview of Arterial Thrombosis clinical trials scenario. This report provides top line data relating to the clinical trials on Arterial Thrombosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Arteriosclerosis Global Clinical Trials Review, H1, 2017

Arteriosclerosis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Arteriosclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Arteriosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Arteriosclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Arteriovenous Fistula Global Clinical Trials Review, H1, 2017

Arteriovenous Fistula Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Arteriovenous Fistula Global Clinical Trials Review, H1, 2017" provides an overview of Arteriovenous Fistula clinical trials scenario. This report provides top line data relating to the clinical trials on Arteriovenous Fistula. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500